![]() students, postdoctoral fellows, and research associates. Group members include a diverse mixture of members including undergraduates, M.Sc. ![]() The Price Research Group operates out of the University of Saskatchewan (USask) Chemistry Department. ![]() While the outage resulted in an unanticipated disruption in the delivery of care for patients, licensed equipment (although non-operational) and nuclear substances at the facility, remained safe during this time.Creating new chemical tools for the construction of next-generation molecular imaging and radionuclide therapy drugsĭepartment of Chemistry, University of Saskatchewan, Saskatoon, Canada Information was shared on an ongoing basis via the IT Systems Outage webpage and News Centre.Įastern Health reported this event to the CNSC, as required. Regular operations resumed on November 22, 2021. The production of radiopharmaceuticals was affected due to the October 30, 2021, cyber-attack that impacted health-care information technology (IT) systems across the province. There were no impacts to patients or the environment, or safety concerns associated with this loss of utility occurrence. The Nuclear and Molecular Medicine facility experienced a loss of utility on the following date in 2022: In addition, FDG was shipped into the province during this maintenance period to further alleviate patient delays for their PET/CT scan.Īn additional period of routine preventative maintenance is currently scheduled to begin in July 2023. The impact to the clinical program was minimal as additional PET procedures were performed prior to and following the maintenance period. The cyclotron, which produces radiotracers for PET-CT procedures, underwent routine preventative maintenance in 2023 during the following dates: February 20 to March 3, 2023. Appendix B: Public Disclosure Summary 2021 (PDF).Appendix A: Public Disclosure Protocol (PDF).Eastern Health – Radiopharmaceutical Sciences Radiation Safety Public Disclosure Program Report (Januto December 31, 2021) (PDF).items of concern (e.g.: impact of natural events, unplanned significant interruptions of facility operations) and.Annual Compliance and Annual Radiation Safety Public Disclosure Report Summary.The following items are communicated via the public disclosure protocol: ![]() 18F-FDG is produced on-site using the cyclotron, while 68Ga-Dotatate is prepared on-site using a Netspot cold kit and Gallium generator. This success marks the second radiopharmaceutical being produced or prepared at the cyclotron and processing facility. Patients across the province can now benefit from receiving this type of PET scan at the Nuclear and Molecular Medicine facility. This locally prepared radiopharmaceutical is used in PET scans performed for the diagnosis and management of neuroendocrine tumors (NETs). October 17, 2022: RPS performed its first clinical preparation of Gallium Dotatate (68Ga-Dotatate) via a Netspot cold kit. The 300 th production of 18F-FDG is another major step towards a more reliable PET service for all Newfoundlanders and Labradorians. March 15, 2023: RPS achieved its 300 th clinical production of 18F-FDG, with 3,714 patients receiving the locally produced radiopharmaceutical for their PET/CT scan. This milestone marked the beginning of the facility’s ability to produce radiopharmaceuticals for use in medicine and research. In August 2020, Eastern Health completed commissioning of the cyclotron particle accelerator and its first medical radiopharmaceutical, FDG. The two principal federal regulatory agencies involved are the Canadian Nuclear Safety Commission (CSNC) and Health Canada. Cyclotron commissioningĮastern Health follows the safety guidelines issued by the Canadian Nuclear Safety Commission to ensure that all individuals are kept safe during all facility operations. The radiopharmaceutical sciences (RPS) team is responsible for manufacturing medical isotopes and radiopharmaceuticals through the use of a cyclotron (particle accelerator).Įastern Health holds a Class II license for the operation of the cyclotron, issued by the Canadian Nuclear Safety Commission (CNSC). To learn more about PET scans, including frequently asked questions, please visit the PET Scan webpage. The product FDG is used in positron emission tomography, commonly known as PET scans. Production of 18F-Fluorodeoxyglucose, commonly referred to as FDG, began at the Health Sciences Centre in November 2020. Eastern Health’s cyclotron is located at the Nuclear and Molecular Medicine facility ( Health Sciences Centre).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |